This review provides an update of knowledge regarding venous thromboembolism (VTE)
and combined hormonal contraceptives (CHCs) in the light of new progestins and new …

Combined oral contraceptives and combined oral postmenopausal hormone therapy are
associated with a weak, but clinically significant risk of arterial and venous thrombosis (VT) …

The present invention has determined that exogenously added glycosylceramide (GlcCer)
and other neutral gly colipids Such as the homologous Glc-containing globotriao …

OBJECTIVE: To review the effects of non-oral administration of postmenopausal hormone
therapy (HT) on risk markers for atherosclerotic and venous thromboembolic disease. Non …

The search for a safe and effective method of contraception has been ongoing for centuries.
During the last century, a variety of hormonal contraceptives, including combined hormonal …

Combined oral contraceptives (COCs) induce several changes in the levels of coagulation
factors. The levels of procoagulant factors are often increased, while levels of anticoagulant …

Deep venous thrombosis (DVT) and pulmonary embolism (PE) are generally considered to
be different but related manifestations of a single disease process, venous …

INTRODUCTION: Hormone therapy (HT) is the most effective treatment to counteract
menopauserelated symptoms. Because venous thromboembolism (VTE) is the main harmful …

Hemostasis in women is influenced by physiological changes in hormone status associated
with the menstrual cycle, pregnancy and hormone-based contraceptives, and hormone …

Desogestrel (DSG) is a less-androgenic progestogen than levonorgestrel (LNG). This
difference in androgenicity may be responsible for observed differences in metabolic effects …